National Wide Cross-sectional Study in Paediatric Central Nervous System Tumours in China -- the CNOG-MC001 Registry

NCT ID: NCT04351035

Last Updated: 2021-09-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

4303 participants

Study Classification

OBSERVATIONAL

Study Start Date

2018-10-27

Study Completion Date

2021-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tumours of central nervous system (CNS) is the most common type of solid tumour in childhood. In China, there is limited epidemiology information. Released data from Chinese CDC did not include types of CNS tumours and geographic contribution. As the Children's Neuro-Oncology Group (CNOG) was established in China in May 2017, it makes studies from multiple centers in children's brain tumors become practical. This retrospective cross-sectional study was aligned on CNOG annual meeting in 2018 and research group was named as CNOG-MC001 (MC, multicenter) collaborative group.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

CNS tumours are mostly seen solid tumours in childhood , as the second common malignancy following leukemia in children. The annual age-standardized incidence rate per 1,000,000 person-years (ASR) of CNS tumour in international children's cancer incidence study is 20-30. In Asia, ASR of paediatric CNS tumours is around 15.0-24.9 in Japan, Korea, Singapore. For Chinese races including mainland of China, Taiwan and Hong Kong, ASRs of paediatric CNS tumour are 15.0, 17.4 and 23.8.

In 2017 in Shanghai, Children's Neuro-Oncology Group (CNOG) was found in 5th CSPN (Chinese Society of Pediatric Neurosurgery) / 9th CPNF (China Pediatric Neurosurgery Forum) conference, with 35 founding member institutions and 30 founding observation member institutions in mainland of China. Based on this progress, national wide registry (CNOG-MC001) was settled to obtain basic information about CNS tumour cases, combined with available epidemiology data from publications to assess current medical situation on paediatric CNS tumours in China. The protocol of CNOG-MC001 was aligned by CSPN and CNOG member institutions in CNOG annual meeting in 2018 and the study ofiicially started right after the meeting on 20181027.

The first step of this study is a national wide pre-survey to all 35 CNOG member institutions and other 22 CSPN members. The pre-survey data sheet included number of annual surgically treated paediatric CNS tumour cases (age ranging from 0 to 18 years old, classified by WHO Classification of Tumours of the Central Nervous System 2016 version), to assess the proper sites to be involved in this study. After retrieving the pre-survey results, large-scale, detailed case data sheets will be sent to participating institutions as members of CNOG-MC001 collaborative group.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tumors, Central Nervous System Pediatric Brain Tumor Malignant Brain Tumor Benign Brain Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Children with CNS tumours

Patients newly diagnosed with CNS tumours in children younger than 18 y/o, who were under in-patient treatment, were labeled as candidate cases in the CNOG-MC001 cohort for reviewing.

Tumour resection

Intervention Type PROCEDURE

It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tumour resection

It is mandatory that patients recieve surgical treatment for pathological diagnosis of CNS tumours in enrolled patients. Surgical resection of tumours could be regarded as total / subtotal / partial resection and biopsy.

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* patients who were newly diagnosed with CNS tumour admitted for in-patient treatments during period of Jan.1st 2016 to Dec. 31st 2017
* patients who were less than 18 year-old at diagnosis
* patients with available mandatory information as age, gender during enrollment
* patients must have pathological diagnosis of tumours, which followed 2016 edition of the World Health Organization (WHO) Classification of Tumours of the Central Nervous System (CNS), except the following conditions:

1. Diffuse Intrinsic Pontine Glioma (DIPG) according to classic symptoms and typical MRI
2. confirmed NF1 patients with classic symtoms and MRI representing Optic Pathway Glioma (OPG) with no surgical treatment indications will be marked as "pilocytic astrocytoma"
3. patients with newly diagnosed recurrence or metastasis of previously confirmed (before Jan.1st 2016) Embryonal Tumours (medulloblastoma, emryonal tumour with multilayered rosettes - C19MC altered, atypical teratoid / rhabdoid tumour / others) and high grade gliomas (glioblastoma, anaplastic astrocytoma) that were unwilling to recieve second surgical treatment / inoperable / without surgical indication, will be marked as original diagnosis
4. patients with newly diagnosed relapse of previously confirmed (before Jan.1st 2016) low grade glioma (defined as pilocytic astrocytoma, diffuse astrocytoma, pilomyxoid astrocytoma, pleomorphic xanthoastrocytoma, subependymal giant cell astrocytoma, oligodendroglioma, oligoastrocytoma, ganglioglioma, desmoplastic infantile astrocytoma and ganglioglioma, dysembryoplastic neuroepithelial tumour, papillary glioneuronal tumour, rosette-forming glioneuronal tumour of the fourth ventricle, angiocentric glioma, dysplastic cerebellar gangliocytoma, extraventricular neurocytoma, cerebellar liponeurocytoma, and central neurocytoma) and ependymal tumours in cross-sectional period, who were unwilling to be operated / inoperable / without surgical indication, will be marked as original diagnosis
* clinical, image and pathology data of patients with unidentified pathological diagnosis from member sites of CNOG-MC001 collaborative group will be sent to study center for reviewing; cases with unidentifiable diagnosis after center review and alignment with CNOG-MC001 sites will be marked as "unknown"

Exclusion Criteria

* confirmed CNS metatasis patients whose tumour tissues were obtained from other systems other than CNS will be excluded
* patients with newly diagnosed recurrence or metastasis of previously confirmed CNS Tumours, will be excluded when primary tumour diagnosis and progression time points were both in cross-sectional period; these patients will be only enrolled as "newly diagnosed cases with primary tumours" and recorded as "progressed in follow-up" in follow-up data sheet
* patients with newly diagnosed relapse of previously confirmed (before Jan.1st 2016) low grade glioma and ependymal tumours, who were unwilling to be operated / inoperable, and were suspected as malignant transformation, will be excluded due to lack of pathological diagnosis
* patients with insufficient or inconsistant data (e.g: patient diagnosed with primary medulloblastoma with tumour located in cerebral) will be excluded in center review after consulting with data-upload institutions
Maximum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

CNOG-MC001 Collaborative Group

UNKNOWN

Sponsor Role collaborator

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Jie Ma, MD, PhD

Director of Dept Pediatric Neurosurgery

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jie MA, M.D., Ph.D.

Role: STUDY_CHAIR

Xinhua Hospital, Shanghai Jiao Tong University School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Anhui Provincial Children's Hospital

Hefei, Anhui, China

Site Status

Beijing Tiantan Hospital, Capital Medical University

Beijing, Beijing Municipality, China

Site Status

Children's Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, China

Site Status

the First Hospital Affiliated To Army Medical University

Chongqing, Chongqing Municipality, China

Site Status

Army Medical Center of PLA

Chongqing, Chongqing Municipality, China

Site Status

the First Affiliated Hospital of Fujian Medical University

Fuzhou, Fujian, China

Site Status

900 Hospital of the Joint Logistics Team of PLA

Fuzhou, Fujian, China

Site Status

Lanzhou University Second Hospital

Lanzhou, Gansu, China

Site Status

Guangdong 999 Brain Hospital

Guangzhou, Guangdong, China

Site Status

Affiliated Hospital of Guilin Medical University

Guilin, Guangxi, China

Site Status

Affiliated Hospital of Zunyi Medical College

Zunyi, Guizhou, China

Site Status

the Second Hospital of Hebei Medical University

Shijiazhuang, Hebei, China

Site Status

the First Affiliated Hospital of Harbin Medical University

Harbin, Heilongjiang, China

Site Status

Children's Hospital Affiliated to Zhengzhou University

Zhengzhou, Henan, China

Site Status

the Third Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, China

Site Status

Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology

Wuhan, Hubei, China

Site Status

Renmin Hospital of Wuhan University / Hubei General Hospital

Wuhan, Hubei, China

Site Status

the Fifth Affiliated Hospital of Zhengzhou University

Zhengzhou, Hunan, China

Site Status

the Second Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status

the First Affiliated Hospital of Soochow University

Suzhou, Jiangsu, China

Site Status

Jiangxi Provincial Children's Hospital

Nanchang, Jiangxi, China

Site Status

the First Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, China

Site Status

the First Bethune Hospital of Jilin University

Ch’ang-ch’un, Jilin, China

Site Status

Shengjing Hospital Affiliated to China Medical University

Shenyang, Liaoning, China

Site Status

the General Hospital of Ningxia Medical University

Yinchuan, Ningxia, China

Site Status

Xi'an Children's Hospital

Xi'an, Shaanxi, China

Site Status

Xijing Hospital of Air Force Military Medical University

Xi'an, Shaanxi, China

Site Status

Qilu Hospital of Shandong University

Jinan, Shandong, China

Site Status

Qilu Children's Hospital of Shandong University

Jinan, Shandong, China

Site Status

Huashan Hospital, Fudan University

Shanghai, Shanghai Municipality, China

Site Status

Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, China

Site Status

Children's Hospital of Fudan University

Shanghai, Shanghai Municipality, China

Site Status

the Children's Hospital of Shanxi Province

Taiyuan, Shanxi, China

Site Status

Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital

Chengdu, Sichuan, China

Site Status

Affiliated Hospital of Southwest Medical University

Luzhou, Sichuan, China

Site Status

People's Hospital of Xinjiang Uygur Autonomous Region

Ürümqi, Xinjiang Uygur Autonomous Region, China

Site Status

Kunming Children's Hospital

Kunming, Yunnan, China

Site Status

the Children's Hospital, Zhejiang University School of Medicine

Hanzhou, Zhejiang, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CNOG-MC001

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.